Trial record 8 of 35 for:
Open Studies | "Potassium"
Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by University of Texas Southwestern Medical Center.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
University of Texas Southwestern Medical Center
Information provided by:
University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT01074918
First received: February 23, 2010
Last updated: March 5, 2010
Last verified: April 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this study is to compare the effects of Potassium Magnesium Citrate to Potassium Chloride on blood pressure among patients with pre-hypertension or mild hypertension. We will also test whether Potassium Magnesium Citrate increases excretion of large amounts of sodium in the urine.
| Condition | Intervention | Phase |
|---|---|---|
|
Pre-Hypertension Hypertension |
Drug: Potassium, Magnesium, Citrate Drug: Potassium Chloride |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Supportive Care |
| Official Title: | Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients; Role of Natriuresis |
Resource links provided by NLM:
Drug Information available for:
Potassium bicarbonate
Sodium citrate
Magnesium citrate
Magnesium
Potassium chloride
Chlorine
U.S. FDA Resources
Further study details as provided by University of Texas Southwestern Medical Center:
Primary Outcome Measures:
- Blood Pressure [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]We have estimated to detect a 4 mmHg difference, with a standard deviation estimated at 8 mmHg.
| Estimated Enrollment: | 42 |
| Study Start Date: | September 2009 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Potassium Magnesium Citrate |
Drug: Potassium, Magnesium, Citrate
Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
|
| Active Comparator: Potassium Chloride |
Drug: Potassium Chloride
Potassium Chloride
|
Eligibility| Ages Eligible for Study: | 21 Years to 95 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Age greater than 21 years
- BMI > 18.5 kg/m2 and < 40 kg/m2
- Prehypertension and mild hypertension: BP systolic 120-159 mmHg, diastolic 80-95 mmHg
- Must agree to limit lifestyle changes including: 1) embarking on a new exercise or weight reduction program 2) altering alcohol intake during the trial.
Exclusion Criteria:
- Taking blood pressure lowering medication
- Diabetes mellitus
- Renal disease
- Active cardiac disease
- Active liver disease
- Chronic diarrhea
- Chronic NSAID use
- Active or suspected drug use
- Uncontrolled psychiatric disease
- HIV infection
- Missed more than 20% of clinic visits in the last yr
- Prescription of diuretics for any reason
- A patient taking nutritional supplements including multivitamins that is unwilling to discontinue them,\
- Consumption of greater than 14 alcoholic beverages per week
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01074918
Contacts
| Contact: Rubina Muzina | 214-857-1909 | Rubina.Muzina@va.gov |
| Contact: Essam Elsayed, MD | 214-857-1908 | Elsam.Elsayed@va.gov |
Locations
| United States, Texas | |
| Dallas VA Medical Center | Recruiting |
| Dallas, Texas, United States, 75216 | |
| Contact: Rubina Muzina 214-857-1909 Rubina.Muzina@va.gov | |
| Contact: Essam Elsayed, MD 214-857-1908 Essam.Elsayed@va.gov | |
| UT Southwestern Medical Center | Active, not recruiting |
| Dallas, Texas, United States, 75390 | |
Sponsors and Collaborators
University of Texas Southwestern Medical Center
More Information
No publications provided
| Responsible Party: | Orson Moe, MD, UT Southwestern Medical Center |
| ClinicalTrials.gov Identifier: | NCT01074918 History of Changes |
| Other Study ID Numbers: | 012007-080 |
| Study First Received: | February 23, 2010 |
| Last Updated: | March 5, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Texas Southwestern Medical Center:
|
Pre-hypertension Hypertension |
Additional relevant MeSH terms:
|
Hypertension Prehypertension Vascular Diseases Cardiovascular Diseases Citric Acid Magnesium citrate Anticoagulants |
Hematologic Agents Therapeutic Uses Pharmacologic Actions Chelating Agents Molecular Mechanisms of Pharmacological Action Cathartics Gastrointestinal Agents |
ClinicalTrials.gov processed this record on May 16, 2013